Beijing Aleeto Biotechnology

Beijing Aleeto Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of next-generation cell therapies for oncology. The company focuses on overcoming the inherent challenges of treating solid tumors using its proprietary Chimeric Antigen Receptor T-cell (CAR-T) and CAR-NK cell platforms. Its research pipeline includes several candidates targeting well-characterized tumor antigens such as Mesothelin and Glypican-3, aimed at indications like liver, pancreatic, and ovarian cancers. By utilizing advanced genetic engineering and optimized manufacturing processes, Aleeto aims to improve the infiltration and persistence of engineered cells within the immunosuppressive tumor microenvironment. The company is positioned within the vibrant biotechnology ecosystem of Beijing, contributing to the advancement of adoptive cell transfer technologies.